Based on the apparent role of BCMA in SLE pathogenesis, we aimed to analyze the expression of BCMA on freshly isolated B cell subsets in SLE patients under conventional and BAFF-targeting therapy with belimumab, which confirms and extends previous results, and demonstrate that increased BCMA expression on B cells is a common and reproducible feature of SLE. The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.